Novozymes A/S (NVZMF)
OTCMKTS
· Delayed Price · Currency is USD
72.25
+0.20 (0.27%)
Jun 5, 2025, 2:01 PM EDT
Novozymes Revenue
Novozymes had revenue of 1.08B EUR in the quarter ending March 31, 2025, with 26.26% growth. This brings the company's revenue in the last twelve months to 4.06B, up 53.93% year-over-year. In the year 2024, Novozymes had annual revenue of 3.83B with 59.58% growth.
Revenue (ttm)
4.06B EUR
Revenue Growth
+53.93%
P/S Ratio
7.76
Revenue / Employee
383.44K EUR
Employees
10,582
Market Cap
34.05B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.83B | 1.43B | 59.58% |
Dec 31, 2023 | 2.40B | 42.38M | 1.80% |
Dec 31, 2022 | 2.36B | 348.99M | 17.36% |
Dec 31, 2021 | 2.01B | 128.32M | 6.82% |
Dec 31, 2020 | 1.88B | -41.10M | -2.14% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Monarch Cement Company | 256.69M |
Rubber Leaf | 3.98M |
Cardinal Ethanol, LLC | 350.34M |
Gold Reserve | 2.63M |
Panamera Holdings | 102.44K |
Venator Materials | 1.56B |
Novozymes News
- 6 days ago - Novonesis: Industry Leader With Defensive Characteristics And Solid Growth - Seeking Alpha
- 27 days ago - Novonesis A/S (NVZMF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales - Benzinga
- 2 months ago - Tariffs create uncertainty and pause investment, says Novonesis CEO - CNBC
- 3 months ago - Novonesis A/S (NVZMF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Novonesis: Still Too Expensive - Seeking Alpha
- 4 months ago - Exciting prospects in bioenergy and functional foods, Novonesis CEO says - CNBC
- 6 months ago - Top 3 global stocks poised for 40% gains by 2025 - Invezz